Eiger BioPharmaceuticals Inc, Applied Therapeutics, Ultragenyx Pharmaceutical, Dicerna Pharmaceuticals, and Imara Inc at Citi BioPharma Conference (Virtual) - Panel Transcript
I hope everyone can hear me. Welcome to the session on challenges and opportunity of rare disease drug development. I'm Yigal Nochomovitz, I'm the biotech analyst at Citi. As always, if you have questions during the session, you're welcome to email me at [email protected] or showcase feature on the video to assist in answering questions that way.
So it's my great pleasure to have with me this afternoon 5 English CEOs of rare disease companies. From Applied Therapeutics, Shoshana Shendelman, CEO; from Dicerna, Doug Fambrough, CEO as well; from Eiger, David Cory, President and CEO; from IMARA, Rahul Ballal, CEO; and from Ultragenyx, Emil Kakkis, President and CEO.
So thank you all so much for joining this afternoon.
Questions & Answers
Maybe as a -- just as a broad high-level question. I'd love to get your thoughts on design considerations for rare disease trials. What should be avoided when
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
